Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically or cytologically confirmed adrenocortical carcinoma * Recurrent, metastatic, or primary unresectable disease * Measurable disease, defined as ≥ 1 lesion accurately measured in ≥ 1 dimension as ≥ 2.0 cm by conventional techniques or ≥ 1.0 cm by spiral CT scan * No adrenocortical tumors that, in the Principal Investigator's opinion, are potentially resectable by surgical excision alone * No symptomatic or progressive brain metastases * Patients with treated brain metastases ≥ 6 months prior to study who are clinically and radiographically stable or improved and are off steroids are eligible * Must undergo an MRI of the brain or CT scan of the head with contrast ≤ 4 weeks prior to study * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 or Karnofsky PS 60-100% * Life expectancy ≥ 12 weeks * White blood cell count (WBC) ≥ 3,000/mm3 * Absolute neutrophil count (ANC) ≥ 1,500/mm3 * Platelet count ≥ 100,000/mm3 * Total bilirubin \< 1.5 mg/dL * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal * Serum creatinine ≤ 1.7 mg/dL or creatinine clearance ≥ 40 mL/min * Able to take oral medications on a regular basis * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception prior to, during, and for ≥ 1 month after completion of study treatment * No HIV positivity * No uncontrolled intercurrent illness including, but not limited t…